logo
Plus   Neg
Share
Email

Merck: FDA Approves Second Biomarker-Based Indication For KEYTRUDA

Merck (MRK) announced the FDA has approved KEYTRUDA as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The indication is approved under accelerated approval.

"For the second time, KEYTRUDA monotherapy is now approved based on a biomarker rather than the location in the body where the tumor originated," said Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories.

The FDA also approved FoundationOne CDx test as the companion diagnostic to identify patients with solid tumors that are TMB-H who may benefit from immunotherapy treatment with KEYTRUDA monotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT